AU754928B2 - Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response - Google Patents

Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response Download PDF

Info

Publication number
AU754928B2
AU754928B2 AU93642/98A AU9364298A AU754928B2 AU 754928 B2 AU754928 B2 AU 754928B2 AU 93642/98 A AU93642/98 A AU 93642/98A AU 9364298 A AU9364298 A AU 9364298A AU 754928 B2 AU754928 B2 AU 754928B2
Authority
AU
Australia
Prior art keywords
disease
antigen
cells
hepatitis
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU93642/98A
Other languages
English (en)
Other versions
AU9364298A (en
Inventor
Edgar G. Engleman
Frederich W. Kuhne
Michael Mcgrath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxo Chemie AG
Original Assignee
Oxo Chemie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxo Chemie AG filed Critical Oxo Chemie AG
Publication of AU9364298A publication Critical patent/AU9364298A/en
Application granted granted Critical
Publication of AU754928B2 publication Critical patent/AU754928B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU93642/98A 1997-10-06 1998-10-06 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response Ceased AU754928B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6095397P 1997-10-06 1997-10-06
US60/060953 1997-10-06
PCT/IB1998/001676 WO1999017787A2 (en) 1997-10-06 1998-10-06 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response

Publications (2)

Publication Number Publication Date
AU9364298A AU9364298A (en) 1999-04-27
AU754928B2 true AU754928B2 (en) 2002-11-28

Family

ID=22032774

Family Applications (1)

Application Number Title Priority Date Filing Date
AU93642/98A Ceased AU754928B2 (en) 1997-10-06 1998-10-06 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response

Country Status (12)

Country Link
US (4) US20050129784A1 (enExample)
EP (1) EP1021196B1 (enExample)
JP (1) JP4369615B2 (enExample)
CN (1) CN1152691C (enExample)
AT (1) ATE258799T1 (enExample)
AU (1) AU754928B2 (enExample)
CA (1) CA2306273A1 (enExample)
DE (1) DE69821506T2 (enExample)
DK (1) DK1021196T3 (enExample)
ES (1) ES2217582T3 (enExample)
PT (1) PT1021196E (enExample)
WO (1) WO1999017787A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148189A0 (en) * 1999-08-18 2002-09-12 Oxo Chemie Ag Chemically-stabilized chlorite solutions for treating cancer and other diseases
AU2011205095B2 (en) * 2004-02-03 2014-07-03 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US8067035B2 (en) 2005-12-22 2011-11-29 Neuraltus Pharmaceuticals, Inc. Chlorite formulations, and methods of preparation and use thereof
WO2008145376A1 (en) * 2007-06-01 2008-12-04 Dimethaid Ag Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis
EA201290041A1 (ru) * 2009-08-06 2012-07-30 Ньюралтус Фармасьютикалс, Инк. Лечение расстройств, связанных с макрофагами
US9266957B2 (en) 2009-11-10 2016-02-23 Mayo Foundation For Medical Education And Research Methods and materials for treating renal cell carcinoma and glioblastoma multiforme
RU2014130080A (ru) 2011-12-22 2016-02-10 Нуво Рисерч Гмбх Липосомальные композиции хлоритов или хлоратов
CN104519890A (zh) * 2012-01-19 2015-04-15 Ibt美国公司 四氯十氧(tcdo)的治疗应用
WO2014078272A1 (en) 2012-11-13 2014-05-22 Mayo Foundation For Medical Education And Research Methods and materials for assessing immune system profiles
US10094835B2 (en) 2013-05-09 2018-10-09 Mayo Foundation For Medical Education And Research Treating patients based on immune subtypes
US11813234B2 (en) 2015-08-20 2023-11-14 Oxo Translational Science Gmbh Use of chlorite to treat red blood cell diseases and indications mediated thereby

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0200157A2 (de) * 1985-05-02 1986-11-05 OXO Chemie GmbH Verwendung einer wässrigen stabilisierten Chloritmatrixlösungzur Herstellung von Arzneimitteln zur intravenösen Applikation bei infektiösenZuständen
US4851222A (en) * 1988-01-27 1989-07-25 Oxo Chemie Gmbh Method of promoting regeneration of bone marrow
WO1996028173A1 (en) * 1994-12-23 1996-09-19 Bioxy Incorporated Biocidal compositions containing halides and oxyhalides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4574084A (en) * 1983-02-25 1986-03-04 Peter Berger Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof
DE3515745A1 (de) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg Waessrige chloritmatrix-loesung
US4956184A (en) * 1988-05-06 1990-09-11 Alcide Corporation Topical treatment of genital herpes lesions
DE4208828A1 (de) * 1992-03-19 1993-09-23 Oxo Chemie Gmbh Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen
US5877222A (en) * 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
WO2008145376A1 (en) * 2007-06-01 2008-12-04 Dimethaid Ag Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0200157A2 (de) * 1985-05-02 1986-11-05 OXO Chemie GmbH Verwendung einer wässrigen stabilisierten Chloritmatrixlösungzur Herstellung von Arzneimitteln zur intravenösen Applikation bei infektiösenZuständen
US4851222A (en) * 1988-01-27 1989-07-25 Oxo Chemie Gmbh Method of promoting regeneration of bone marrow
WO1996028173A1 (en) * 1994-12-23 1996-09-19 Bioxy Incorporated Biocidal compositions containing halides and oxyhalides

Also Published As

Publication number Publication date
EP1021196A2 (en) 2000-07-26
PT1021196E (pt) 2004-06-30
US20120141514A1 (en) 2012-06-07
DE69821506T2 (de) 2004-12-16
CN1306433A (zh) 2001-08-01
WO1999017787A3 (en) 1999-06-17
CN1152691C (zh) 2004-06-09
DE69821506D1 (de) 2004-03-11
CA2306273A1 (en) 1999-04-15
EP1021196B1 (en) 2004-02-04
US20110076344A1 (en) 2011-03-31
ATE258799T1 (de) 2004-02-15
AU9364298A (en) 1999-04-27
ES2217582T3 (es) 2004-11-01
JP4369615B2 (ja) 2009-11-25
JP2001518512A (ja) 2001-10-16
WO1999017787A2 (en) 1999-04-15
DK1021196T3 (da) 2004-06-07
US20090004295A1 (en) 2009-01-01
US20050129784A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
US20090004295A1 (en) Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
Penack et al. Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors
Alpdogan et al. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease
Hamblin Ultraviolet irradiation of blood:“the cure that time forgot”?
US20150056678A1 (en) Disease therapy using dying or dead cells
Wang et al. Interleukin‐10 induces macrophage apoptosis and expression of CD16 (FcγRIII) whose engagement blocks the cell death programme and facilitates differentiation
EP2941257A1 (en) Disease therapy using a tolerogenic pharmaceutical preparation
Bhattacharyya et al. Multilineage engraftment with minimal graft-versus-host disease following in utero transplantation of S-59 psoralen/ultraviolet a light-treated, sensitized T cells and adult T cell-depleted bone marrow in fetal mice
Buhler et al. CD40-CD154 pathway blockade requires host macrophages to induce humoral unresponsiveness to pig hematopoietic cells in baboons
Firdessa-Fite et al. Soluble antigen arrays provide increased efficacy and safety over free peptides for tolerogenic immunotherapy
Del Rosario et al. Prevention of graft-versus-host disease by induction of immune tolerance with ultraviolet B-irradiated leukocytes in H-2 disparate bone marrow donor
AU6913200A (en) Chemically-stabilized chlorite solutions for treating cancer and other diseases
WO2024099363A1 (zh) Rip2抑制剂联合免疫检查点抑制剂药物组合物及其应用
Cohn et al. Hematopoietic reconstitution and prevention of graft-versus-host disease with UVB-irradiated haploidentical murine spleen and marrow cells
Koulmanda et al. Fetal pig islet xenografts in NOD/Lt mice: The effect of peritransplant anti‐CD4 monoclonal antibody and graft immunomodification on graft survival, and lack of expression of Gal (α1–3) Gal on endocrine cells
Rosenfeld et al. Ex vivo purging of allogeneic marrow with L-leucyl-L-leucine methyl ester: a phase I study
Hofmann et al. Activity of phagocytic granulocytes in patients with prostatic cancer
Baron et al. Failure of donor lymphocyte infusion to prevent graft rejection in dogs given DLA-identical marrow after 1 Gy of total body irradiation
Budde et al. Dendritic polyglycerol sulfate attenuates murine graft-versus-host disease
Wang et al. Mechanism Development of Accommodation and Tolerance in Transplant
Tanaka et al. Hyperresponsiveness of granulocytes to anaphylatoxins, C5a and C3a, in Churg-Strauss syndrome
Sheng-Tanner et al. Characterization of graft-versus-host disease in SCID mice and prevention by physicochemical stressors
Zhou et al. of November 10, 2015.
Dubey et al. Susceptibility and resistance to autoimmunity following neonatal injection of semi-allogeneic spleen cells in rats
Miller Potential mechanisms explaining the antitumor effect of total-body irradiation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)